Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CDT
Upturn stock ratingUpturn stock rating

Conduit Pharmaceuticals Inc. (CDT)

Upturn stock ratingUpturn stock rating
$1.35
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: CDT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -33.52%
Avg. Invested days 63
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 2.74M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 2
52 Weeks Range 2.21 - 1560.00
Updated Date 06/29/2025
52 Weeks Range 2.21 - 1560.00
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -255.6

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -168.26%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3484180
Price to Sales(TTM) -
Enterprise Value 3484180
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -55.41
Shares Outstanding 952229
Shares Floating 552357
Shares Outstanding 952229
Shares Floating 552357
Percent Insiders 18.39
Percent Institutions 3.63

ai summary icon Upturn AI SWOT

Conduit Pharmaceuticals Inc.

stock logo

Company Overview

overview logo History and Background

Conduit Pharmaceuticals Inc., founded in 2020, focuses on developing and commercializing innovative treatments targeting unmet medical needs. It aims to in-license and develop promising therapies from academic institutions and other pharmaceutical companies.

business area logo Core Business Areas

  • In-licensing and Development: Acquiring rights to promising drug candidates and advancing them through preclinical and clinical development.
  • Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of drug candidates.
  • Commercialization: Preparing for the commercial launch and marketing of approved therapies.

leadership logo Leadership and Structure

Dr. Fredrik Wiklund serves as the Chief Executive Officer. The company's structure consists of research and development, clinical operations, and commercialization teams.

Top Products and Market Share

overview logo Key Offerings

  • AZD1656: A fructose-1,6-bisphosphatase (FBPase) inhibitor licensed from AstraZeneca. The company plans to initiate a Phase 2 clinical trial in patients with diabetes in H1 2024. Competitors include other diabetes treatments from companies such as Novo Nordisk (NVO) and Eli Lilly (LLY).
  • Remogliflozin etabonate: A selective inhibitor of the sodium glucose co-transporter 2 (SGLT2). The company plans to initiate a Phase 2 clinical trial in patients with diabetes and heart failure in H1 2024. Competitors include other SGLT2 inhibitors from companies such as Johnson & Johnson (JNJ) and Boehringer Ingelheim.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is experiencing growth driven by increasing healthcare spending, aging populations, and advancements in drug development technologies.

Positioning

Conduit Pharmaceuticals is positioned as a company focused on in-licensing and developing promising drug candidates to address unmet medical needs, aiming for niche markets where current treatments are inadequate.

Total Addressable Market (TAM)

The TAM for diabetes and heart failure treatments is estimated to be billions of dollars. Conduit Pharmaceuticals is positioned to capture a share of this market by offering differentiated therapies.

Upturn SWOT Analysis

Strengths

  • Experienced management team
  • Focus on in-licensing de-risked assets
  • Strong pipeline of drug candidates

Weaknesses

  • Dependence on successful clinical trial outcomes
  • Limited financial resources compared to larger pharmaceutical companies
  • High regulatory hurdles and development risks

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Accelerated approval pathways for innovative therapies

Threats

  • Competition from established pharmaceutical companies
  • Failure of clinical trials
  • Changes in regulatory landscape

Competitors and Market Share

competitor logo Key Competitors

  • Novo Nordisk (NVO)
  • Eli Lilly (LLY)
  • Johnson & Johnson (JNJ)

Competitive Landscape

Conduit Pharmaceuticals faces significant competition from established pharmaceutical companies with larger resources and broader product portfolios. Its competitive advantage lies in its focus on in-licensing de-risked assets and developing innovative therapies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited due to the company's recent establishment. Growth is anticipated upon successful clinical trial completion and product commercialization.

Future Projections: Future growth projections depend on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary depending on the success of the pipeline.

Recent Initiatives: Initiating Phase 2 clinical trials for AZD1656 and Remogliflozin etabonate are key recent initiatives.

Summary

Conduit Pharmaceuticals is a young company with potential in developing niche therapies. Its success hinges on successful clinical trials. Competition from established firms poses a significant challenge, and managing its financial resources will be crucial for future growth. The company's in-licensing strategy provides a promising avenue for expanding its portfolio.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • Press Releases
  • Analyst Reports
  • SEC Filings

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual circumstances and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Conduit Pharmaceuticals Inc.

Exchange NASDAQ
Headquaters Naples, FL, United States
IPO Launch date 2023-09-25
Founder, CEO & Director Dr. Andrew Regan
Sector Healthcare
Industry Biotechnology
Full time employees 6
Full time employees 6

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida.